Popular on TelAve
- Meredith Thomas Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Spark Design Award Winners & New 2025 Call For Entry
- Post-Oscar Iftar Night Celebrates Academy Award-Winning Documentary No Other Land with a Packed House
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- CitySwitch and OneVizion Partner to Significantly Reduce Accounting and Lease Administration Costs Annually with ASC 842-Compliant Leasing Solution
- 3DCal.com Launches Revolutionary 3D Graphic Design System for Custom Motorcycle Decals
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
- Rutgers University Student Wins "New Jersey's Top Student Entrepreneur" in EO's Global Student Entrepreneur Awards
- Heartwarming News: UCLA & Lakers Honor Young Fan from New Mexico as "Laker For A Day"
- Jazz Legend Bob Holz Nomination-New Album Honoring Larry Coryell
Similar on TelAve
- Karen Mueller Leads the Charge in Infection Prevention as SterileCare Drives Meaningful Change in Catheter Care
- MANE DRINK to Launch Lion's Mane Mushroom Coffee in April — Pre-Orders Now Open for Nootropic Cold Brew
- 45th International Symposium On Forecasting – Dates, Venue And Speakers Announced
- Protecting Parental Rights: The Fight Against Coerced Mental Health Screening
- Restoration Dental Launches New Website to Enhance Patient Experience
- OneSolution Dental Implant Centers Announces All-on-X Digital Workflow Master Course in Palm Beach, FL
- Lineus Medical Completes $4.6 Million Series C Funding Round
- UN Report Exposes Psychiatric Abuses, Urges End to Forced Treatment Worldwide
- LifeVac, America's Leading Life Saving Device With Over 3000 Lives Saved, Featured on CNBC
- Longevity by Nature Partners with Leabon Group for Exclusive Telos95® Distribution in China
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
TelAve News/10834551
JUPITER, Fla. - TelAve -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on TelAve News
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on TelAve News
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on TelAve News
- Portland's Evolve & Unite Festival Brings a Transformational Experience to the Pacific Northwest
- School Launches 250 Students International Service Trips - Gives $1M to Global Education
- DivX Unveils Enhanced Guide on Converting MOV to MP4 for Effortless Video Conversion
- SourceCode Expands AI Factory Offerings with Atlas AI Ignite at GTC 2025
- Karen Mueller Leads the Charge in Infection Prevention as SterileCare Drives Meaningful Change in Catheter Care
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on TelAve News
- AI — Past, Present, and Future: Verb Presents Features Jay Preston
- New Free St. Patrick's Day Bingo Cards Announced – Print or Play Digitally!
- MANE DRINK to Launch Lion's Mane Mushroom Coffee in April — Pre-Orders Now Open for Nootropic Cold Brew
- Curated for You partners with Microsoft to unlock the future of AI-powered fashion discovery
- OpenSSL 3.1.2 Achieves FIPS 140-3 Validation
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on TelAve News
- The Heart of "Rooted In Rhythm": Bridging Gaps Through Music and Community
- 888BoatLaw.com Awards $1000 For FWC Pink Tag Bass Contest
- Dexter B. Jenkins: Championing Financial Literacy and Empowering Generational Wealth Through Faith-Based Guidance
- Best-Selling Author Maurice I. Crawford Unveils Explosive New Book
- Q4 2024 Industry Impact Report Highlights Shifts in Arizona Tech Employment Trends and Investments
- Webinar Announcement: AI Governance: Balancing Innovation and Responsibility
- Aterna AI Unveils AI Trading System with 67% Annual Returns for Career-Focused Professionals
- RoarFun attracts visitors with a motion flight simulator rental and virtual branding at the London Heathrow Aviation Carbon Sustainability conference
- 35th Annual Safe Sober T-Shirt Design Contest Winner Announced at Career Center High in Winston-Salem, North Carolina
- Expansive Estate in South Texas Seeks New Vision, 147 Acres Up for Grabs
- Events by Dubsdread Unveils the 2025 Orlando Wedding Pricing Guide
- Local Company Gets National Industry Recognition
- OneSolution Dental Implant Centers Announces All-on-X Digital Workflow Master Course in Palm Beach, FL
- Allen Field Co., Inc. Cuts Through the Hype: Real Packaging Solutions, No Buzzwords at Pack Expo Southeast 2025
- Digitek Solutions, an Alta Vista Company, Unveils Next-Generation Hosting Hardware at Arizona Data Center
- Himamauli Das Joins K2 Integrity as Senior Managing Director and Counsel
- Have a Special Japanese Honeymoon Experience in Nikko, Japan, With Photoshoot
- Tone Commander releases next-generation AS-SIP, APL-listed, and TSG-6 certified SIP phone with GigE, POE, and fiber SFP connectivity
- Andrew B. Louis is Working on His 14th Novel, Number 13 Will Be Out This Month
- Post-Oscar Iftar Night Celebrates Academy Award-Winning Documentary No Other Land with a Packed House